Visual symptoms in Parkinson's disease

R A Armstrong, R A Armstrong

Abstract

Parkinson's disease (PD) is a common disorder of middle-aged and elderly people in which degeneration of the extrapyramidal motor system causes significant movement problems. In some patients, however, there are additional disturbances in sensory systems including loss of the sense of smell and auditory and/or visual problems. This paper is a general overview of the visual problems likely to be encountered in PD. Changes in vision in PD may result from alterations in visual acuity, contrast sensitivity, colour discrimination, pupil reactivity, eye movements, motion perception, visual field sensitivity, and visual processing speeds. Slower visual processing speeds can also lead to a decline in visual perception especially for rapidly changing visual stimuli. In addition, there may be disturbances of visuospatial orientation, facial recognition problems, and chronic visual hallucinations. Some of the treatments used in PD may also have adverse ocular reactions. The pattern electroretinogram (PERG) is useful in evaluating retinal dopamine mechanisms and in monitoring dopamine therapies in PD. If visual problems are present, they can have an important effect on the quality of life of the patient, which can be improved by accurate diagnosis and where possible, correction of such defects.

Figures

Figure 1
Figure 1
The layers of the retina (PE: pigment epithelium, PR: visual receptors, ONL: outer nuclear layer, OPL: outer plexiform layer, INL: internal nuclear layer, IPL: internal plexiform layer, GC: ganglion cell layer, and SO: Stratum opticum). Dopamine neurons (TOH+: Tyrosine hydroxylase positive neurons, Type 1 cells and Type 2 amacrine cells) are primarily concentrated in the INL and dopamine positive neurites (Type 1 in stratum 1 and type 2 ramify above stratum 1) in the IPL. Type 1 cells may synapse onto GABA interpelexiform cells (IPCs). Some dopamine activities may also be observed in the ganglion cell layer.
Figure 2
Figure 2
Cells from the cerebral cortex showing the presence of Lewy bodies (α-synuclein immunohistochemistry, haematoxylin stain, bar = 25 μm).
Figure 3
Figure 3
The dopamine projections of the central nervous system (OB: Olfactory bulb, SFC: superior frontal cortex, CG: Cingulate gyrus, ST: Striatum, HY: Hypothalamus, VT: Ventral tegmentum, SN: Substantia nigra).

References

    1. Antal A, Bandini F, Kéri S, Bodis-Wollner I. Visuo-cognitive dysfunctions in Parkinson’s disease. Clinical Neuroscience. 1998;5(supplement 2):147–152.
    1. Armstrong RA. Parkinson’s disease and the eye. Ophthalmic and Physiological Optics. 1997;17(2):S9–S16.
    1. Armstrong RA. Visual signs and symptoms of Parkinson’s disease. Clinical and Experimental Optometry. 2008;91(2):129–138.
    1. Repka MX, Claro MC, Loupe DN, Reich SG. Ocular motility in Parkinson’s disease. Journal of Pediatric Ophthalmology and Strabismus. 1996;33(3):144–147.
    1. Jones RD, Donaldson IM. Fractionation of visuoperceptual dysfunction in Parkinson’s disease. Journal of the Neurological Sciences. 1995;131(1):43–50.
    1. Jones RD, Donaldson IM, Timmings PL. Impairment of high-contrast visual acuity in Parkinson’s disease. Movement Disorders. 1992;7(3):232–238.
    1. Matsui H, Udaka F, Tamura A, et al. Impaired visual acuity as a risk factor for visual hallucinations in Parkinson’s disease. Journal of Geriatric Psychiatry and Neurology. 2006;19(1):36–40.
    1. Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson’s disease. Neurology. 1992;42(4):887–890.
    1. Buttner T, Kuhn W, Klotz P, et al. Disturbance of colour perception in Parkinson’s disease. Journal of Neural Transmission. 1993;6(1):11–15.
    1. Diederich NJ, Raman R, Leurgans S, Goetz CG. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Archives of Neurology. 2002;59(8):1249–1252.
    1. Veselá O, Růžička E, Jech R, et al. Colour discrimination impairment is not a reliable early marker of Parkinson’s disease. Journal of Neurology. 2001;248(11):975–978.
    1. Ture S, Inci I, Gedizlioglu M. Abnormalities of contrast sensitivity, visual fields and visual evoked potentials in Parkinson’s disease and effect of dopaminergic treatment. Journal of Neurology. 2007;254(supplement 3):p. 93.
    1. Bayer AU, Keller ON, Ferrari F, Maag KP. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer’s disease and Parkinson’s disease. American Journal of Ophthalmology. 2002;133(1):135–137.
    1. Biousse V, Newman NJ, Carroll C, et al. Visual fields in patients with posterior GPi pallidotomy. Neurology. 1998;50(1):258–265.
    1. Shibasaki H, Tsuji S, Kuroiwa Y. Oculomotor abnormalities in Parkinson’s disease. Archives of Neurology. 1979;36(6):360–364.
    1. Crawford T, Goodrich S, Henderson L, Kennard C. Predictive responses in Parkinson’s disease: manual keypresses and saccadic eye movements to regular stimulus events. Journal of Neurology Neurosurgery and Psychiatry. 1989;52(9):1033–1042.
    1. Winograd-Gurvich C, Georgiou-Karistianis N, Fitzgerald PB, Millist L, White OB. Self-paced saccades and saccades to oddball targets in Parkinson’s disease. Brain Research. 2006;1106(1):134–141.
    1. Shaunak S, O’Sullivan E, Blunt S, et al. Remembered saccades with variable delay in Parkinson’s disease. Movement Disorders. 1999;14(1):80–86.
    1. Hodgson TL, Dittrich WH, Henderson L, Kennard C. Eye movements and spatial working memory in Parkinson’s disease. Neuropsychologia. 1999;37(8):927–938.
    1. Bares M, Brazdil M, Kanovsky P, et al. The effect of apomorphine administration on smooth pursuit ocular movements in early Parkinson’s disease. Parkinsonism & Related Disorders. 2003;9:139–144.
    1. Corin MS, Elizan TS, Bender MB. Oculomotor function in patients with Parkinson’s disease. Journal of the Neurological Sciences. 1972;15(3):251–265.
    1. Lepore FE. Parkinson’s disease and diplopia. Neuro-Ophthalmology. 2006;30(2-3):37–40.
    1. Biousse V, Skibell BC, Watts RL, Loupe DN, Drews-Botsch C, Newman NJ. Ophthalmologic features of Parkinson’s disease. Neurology. 2004;62(2):177–180.
    1. Garland HG. Refresher course for general practitioners. Parkinsonism. British Medical Journal. 1952;1:153–155.
    1. Peshori KR, Schicatano EJ, Gopalaswamy R, Sahay E, Evinger C. Aging of the trigeminal blink system. Experimental Brain Research. 2001;136(1):351–363.
    1. Micieli G, Tassorelli C, Martignoni E, et al. Disordered pupil reactivity in Parkinson’s disease. Clinical Autonomic Research. 1991;1(1):55–58.
    1. Bulens C, Meerwaldt JD, Van Der Wildt GJ, Van Deursen JBP. Effect of levodopa treatment on contrast sensitivity in Parkinson’s disease. Annals of Neurology. 1987;22(3):365–369.
    1. Hutton JT, Morris JL, Elias JW. Levodopa improves spatial contrast sensitivity in Parkinson’s disease. Archives of Neurology. 1993;50(7):721–724.
    1. Bodis-Wollner I, Marx MS, Mitra S, Bobak P, Mylin L, Yahr M. Visual dysfunction in Parkinson’s disease. Loss in spatiotemporal contrast sensitivity. Brain. 1987;110(6):1675–1698.
    1. Rodnitzky RL. Visual dysfunction in Parkinson’s disease. Clinical Neuroscience. 1998;5(2):102–106.
    1. Büttner TH, Müller TH, Kuhn W. Effects of apomorphine on visual functions in Parkinson’s disease. Journal of Neural Transmission. 2000;107(1):87–94.
    1. Guehl D, Burbaud P, Lorenzi C, et al. Auditory temporal processing in Parkinson’s disease. Neuropsychologia. 2008;46(9):2326–2335.
    1. Harrington DL, Haaland KY, Hermanowicz N. Temporal processing in the basal ganglia. Neuropsychology. 1998;12(1):3–12.
    1. Jones CR, Jahanshahi M. The substantia nigra, the basal ganglia, dopamine and temporal processing. Journal of Neural Transmission. 2009;(73):161–171.
    1. Gottlob I, Schneider E, Heider W, Skrandies W. Alteration of visual evoked potentials and electroretinograms in Parkinson's disease. Electroencephalography & Clinical Neurophysiology. 1987;66:349–357.
    1. Peppe A, Stanzione P, Pierelli F, De Angelis D, Pierantozzi M, Bernardi G. Visual alterations in de novo Parkinson's disease: pattern electroretinogram latencies are more delayed and more reversible by levodopa than are visual evoked potentials. Neurology. 1995;45:1144–1148.
    1. Bodis-Wollner I, Tzelepi A. The push-pull action of dopamine on spatial tuning of the monkey retina: the effects of dopaminergic deficiency and selective D and D receptor ligands on the pattern electroretinogram. Vision Research. 1998;38(10):1479–1487.
    1. Tagliati M, Bodis-Wollner I, Yahr MD. The pattern electroretinogram in Parkinson’s disease reveals lack of retinal spatial tuning. Electroencephalography and Clinical Neurophysiology. 1996;100(1):1–11.
    1. Tagliati M, Bodis-Wollner I, Kovanecz I, Stanzione P. Spatial frequency tuning of the monkey pattern ERG depends on D2 receptor-linked action of dopamine. Vision Research. 1994;34(16):2051–2057.
    1. Stanzione P, Bodis-Wollner I, Pierantozzi M, et al. A mixed D1 and D2 antagonist does not replay pattern electroretinogram alterations observed with a selective D2 antagonist in normal humans: relationship with Parkinson’s disease pattern electroretinogram alterations. Clinical Neurophysiology. 1999;110(1):82–85.
    1. Li M, Kuroiwa Y, Wang L, et al. Early sensory information processes are enhanced on visual oddball and S1-S2 tasks in Parkinson’s disease: a visual event-related potentials study. Parkinsonism and Related Disorders. 2003;9(6):329–340.
    1. Wang L, Kuroiwa Y, Kamitani T, et al. Visual event-related potentials in progressive supranuclear palsy, corticobasal degeneration, striatonigral degeneration, and Parkinson’s disease. Journal of Neurology. 2000;247(5):356–363.
    1. Barbato L, Rinalduzzi S, Laurenti M, Ruggieri S, Accornero N. Color VEPs in Parkinson’s disease. Electroencephalography and Clinical Neurophysiology. 1994;92(2):169–172.
    1. Sartucci F, Orlandi G, Bonuccelli U, et al. Chromatic pattern-reversal electroretinograms (ChPERGs) are spared in multiple system atrophy compared with Parkinson’s disease. Neurological Sciences. 2006;26(6):395–401.
    1. Bodis-Wollner I, Yahr MD. Measurements of visual evoked potentials in Parkinson’s disease. Brain. 1978;101(4):661–671.
    1. Onofrj M, Bosid-Wollner I. Dopaminergic deficiency causes delayed visual evoked potentials in rats. Annals of Neurology. 1982;11(5):484–490.
    1. Bodis-Wollner I, Yahr MD, Mylin L, Thornton J. Dopaminergic deficiency and delayed visual evoked potentials in humans. Annals of Neurology. 1982;11(5):478–483.
    1. Levin BE, Llabre MM, Reisman S, et al. Visuospatial impairment in Parkinson’s disease. Neurology. 1991;41(3):365–369.
    1. Davidsdottir S, Cronin-Golomb A, Lee A. Visual and spatial symptoms in Parkinson’s disease. Vision Research. 2005;45(10):1285–1296.
    1. Trick GL, Kaskie B, Steinman SB. Visual impairment in Parkinson’s disease: deficits in orientation and motion discrimination. Optometry and Vision Science. 1994;71(4):242–245.
    1. Lang PJ. Presidential address, 1978. A bio-informational theory of emotional imagery. Psychophysiology. 1979;16(6):495–512.
    1. Sprengelmeyer R, Young AW, Mahn K, et al. Facial expression recognition in people with medicated and unmedicated Parkinson’s disease. Neuropsychologia. 2003;41(8):1047–1057.
    1. Hodgson TL, Tiesman B, Owen AM, Kennard C. Abnormal gaze strategies during problem solving in Parkinson’s disease. Neuropsychologia. 2002;40(4):411–422.
    1. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson’s disease as disturbed external/internal perceptions: focused review and a new integrative model. Movement Disorders. 2005;20(2):130–140.
    1. Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson’s disease. Prevalence, phenomenology and risk factors. Brain. 2000;123(4):733–745.
    1. Hunt LA, Sadun AA, Bassi CJ. Review of the visual system in Parkinson’s disease. Optometry and Vision Science. 1995;72(2):92–99.
    1. Patil PN, Mauger TF. Cholinergic sensitivity of irides from donors with various pathological conditions and lens implants. Naunyn-Schmiedeberg’s Archives of Pharmacology. 1992;346(6):620–628.
    1. Dowling JE, Ehinger B, Hedden WL. The interplexiform cell: a new type of retinal neuron. Investigative Ophthalmology. 1976;15(11):916–926.
    1. Frederick JM, Rayborn ME, Laties AM. Dopaminergic neurons in the human retina. Journal of Comparative Neurology. 1982;210(1):65–79.
    1. Masson G, Mestre D, Blin O. Dopaminergic modulation of visual sensitivity in man. Fundamental and Clinical Pharmacology. 1993;7(8):449–463.
    1. Djamgoz MBA, Hankins MW, Hirano J, Archer SN. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Research. 1997;37(24):3509–3529.
    1. Nguyen-Legros J, Harnois C, Di Paolo T, Simon A. The retinal dopamine system in Parkinson’s disease. Clinical Vision Sciences. 1993;8(1):1–12.
    1. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. Vision Research. 2004;44(24):2793–2797.
    1. Armstrong RA, Syed AB. Alzheimer’s disease and the eye. Ophthalmic and Physiological Optics. 1996;16(1):S2–S8.
    1. Spillantini MG, Anthony Crowther R, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neuroscience Letters. 1998;251(3):205–208.
    1. Eberling JL, Richardson BC, Reed BC, Wolfe N, Jagust WJ. Cortical glucose metabolism in Parkinson’s disease without dementia. Neurobiology of Aging. 1994;15(3):329–335.
    1. Baglio F, Blasi V, Falini A, et al. Functional brain changes in early Parkinson’s disease during motor response and motor inhibition. Neurobiology of Aging. 2009;32(1):115–124.
    1. Rieger B, Markowitsch HJ. Implicit and explicit mnestic performance of patients with prefrontal, medial temporal, and basal ganglia damage. Neurology Psychiatry and Brain Research. 1996;4(2):53–74.
    1. Basso MA, Pokorny JJ, Liu P. Activity of substantia nigra pars reticulata neurons during smooth pursuit eye movements in monkeys. European Journal of Neuroscience. 2005;22(2):448–464.
    1. Naylor RJ. The ocular effects of parkinsonism and its treatment. Optometry in Practice. 2005;6:19–31.
    1. Friedman Z, Neumann E. Benzhexol-induced blindness in Parkinson’s disease. British Medical Journal. 1972;1(800):p. 605.
    1. Spiers AS, Calne DB, Fayers PM. Miosis during L-dopa therapy. British Medical Journal. 1970;2(7):639–640.
    1. Michell AW, Xu Z, Fritz D, et al. Saccadic latency distributions in Parkinson’s disease and the effects of L-dopa. Experimental Brain Research. 2006;174(1):7–18.
    1. Peters S, Schweibold G, Przuntek H, Muller T. Loss of visual acuity under dopamine substitution therapy. Neuro-Ophthalmology. 2000;24(1):273–277.
    1. Pearlman JT, Kadish AH, Ramseyer JC. Vision loss associated with amantadine hydrochloride use. Journal of the American Medical Association. 1977;237(12):p. 1200.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj